Optical Strain Gauge for High Temperature Plastic Deformation Measurement

Nondestructive evaluation techniques for aging components are becoming very important methods for identification of material degradation, life assessment and development of inspection strategies. In this frame a laser system suited for measurement of permanent deformations in power plant pipes has been designed, built-up and in-field tested

appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies)

n/

Efficient yeast ChIP-Seq using multiplex short-read DNA sequencing

<p>Abstract</p> <p>Background</p> <p>Short-read high-throughput DNA sequencing technologies provide new tools to answer biological questions. However, high cost and low throughput limit their widespread use, particularly in organisms with smaller genomes such as <it>S. cerevisiae</it>. Although ChIP-Seq in mammalian cell lines is replacing array-based ChIP-chip as the standard for transcription factor binding studies, ChIP-Seq in yeast is still underutilized compared to ChIP-chip. We developed a multiplex barcoding system that allows simultaneous sequencing and analysis of multiple samples using Illumina's platform. We applied this method to analyze the chromosomal distributions of three yeast DNA binding proteins (Ste12, Cse4 and RNA PolII) and a reference sample (input DNA) in a single experiment and demonstrate its utility for rapid and accurate results at reduced costs.</p> <p>Results</p> <p>We developed a barcoding ChIP-Seq method for the concurrent analysis of transcription factor binding sites in yeast. Our multiplex strategy generated high quality data that was indistinguishable from data obtained with non-barcoded libraries. None of the barcoded adapters induced differences relative to a non-barcoded adapter when applied to the same DNA sample. We used this method to map the binding sites for Cse4, Ste12 and Pol II throughout the yeast genome and we found 148 binding targets for Cse4, 823 targets for Ste12 and 2508 targets for PolII. Cse4 was strongly bound to all yeast centromeres as expected and the remaining non-centromeric targets correspond to highly expressed genes in rich media. The presence of Cse4 non-centromeric binding sites was not reported previously.</p> <p>Conclusion</p> <p>We designed a multiplex short-read DNA sequencing method to perform efficient ChIP-Seq in yeast and other small genome model organisms. This method produces accurate results with higher throughput and reduced cost. Given constant improvements in high-throughput sequencing technologies, increasing multiplexing will be possible to further decrease costs per sample and to accelerate the completion of large consortium projects such as modENCODE.</p

Multiband Photometry Evolution in the First Weeks of SN 2023ixf, a possible II-L Subtype Supernova

Multiband photometric observations and their evaluation to instrumental magnitudes were performed using standard Johnson-Cousins filters (B, V, Rc) as well r and g Sloan filters, and not standard ones (R, G, B, and Clear filters). These were recorded from 9 observatories and from the MicroObservatory Robotic Telescope Network. The results describe the rapid ascent towards the maximum (2.5 magnitudes about in five days in the B filter) and the slow decrease after the maximum (0.0425 +/- 0.02 magnitudes/day in the B filter). The results highlight the strong variation of the B-V colour indices during the first 50 days (from -0.20 +/- 0.02 to +0.85 +/- 0.02) and V-R (from 0 +/- 0.01 to +0.50 +/- 0.01) after the explosion, presumably corresponding to the cooling of the stellar photosphere. At 50 days after the explosion the magnitude decrease from the maximum was observed to continue where it faded by 2.5 magnitudes (B filter), thus we propose SN 2023ixf is a Type II, subtype L, supernova (SNe)

Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.

Breast cancers enduring treatment with chemotherapy may be enriched for cancer stem cells or tumor-initiating cells, which have an enhanced capacity for self-renewal, tumor initiation, and/or metastasis. Breast cancer cells that express the type I tyrosine kinaselike orphan receptor ROR1 also may have such features. Here we find that the expression of ROR1 increased in breast cancer cells following treatment with chemotherapy, which also enhanced expression of genes induced by the activation of Rho-GTPases, Hippo-YAP/TAZ, or B lymphoma Mo-MLV insertion region 1 homolog (BMI1). Expression of ROR1 also enhanced the capacity of breast cancer cells to invade Matrigel, form spheroids, engraft in Rag2-/-[Formula: see text] mice, or survive treatment with paclitaxel. Treatment of mice bearing breast cancer patient-derived xenografts (PDXs) with the humanized anti-ROR1 monoclonal antibody cirmtuzumab repressed expression of genes associated with breast cancer stemness, reduced activation of Rho-GTPases, Hippo-YAP/TAZ, or BMI1, and impaired the capacity of breast cancer PDXs to metastasize or reengraft Rag2-/-[Formula: see text] mice. Finally, treatment of PDX-bearing mice with cirmtuzumab and paclitaxel was more effective than treatment with either alone in eradicating breast cancer PDXs. These results indicate that targeting ROR1 may improve the response to chemotherapy of patients with breast cancer